Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

Valneva

Status and phase: Completed; Phase 3; Phase 2

Conditions: Pseudomonas Aeruginosa Infection

Treatments: Biological: IC43; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01563263

IC43-202

Details and patient eligibility

About

This is a confirmatory, randomized, placebo-controlled, multi-center, double-blinded phase II/III study. The study population consists of male or female intensive care unit (ICU) patients with a need for mechanical ventilation for more than 48 hours, aged between 18 and 80 years.

Full description

This is a confirmatory, randomized, placebo-controlled, multi-center, double-blinded phase II/III study. The study population consists of male or female intensive care unit (ICU) patients with a need for mechanical ventilation for more than 48 hours, aged between 18 and 80 years.

Eight-hundred patients will be enrolled at approximately 50 study centers. Informed consent (i.e., from the patient or from the patient's legally authorized representative) or waiver will be obtained according to regional requirements prior to any study related procedures. Patients will be randomized to receive either IC43 100 mcg or placebo and will receive the first vaccination on Day 0. The second vaccination will be applied on Day 7. In case ICU discharge occurs before Day 7, immunization will be done at the hospital ward.

Enrollment: 803 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male or female patients admitted to an intensive care unit (ICU) with need for mechanical ventilation for at least 48 hours, aged between 18 and 80 years at Visit 0
• written informed consent or waiver according to the national regulations
• no childbearing potential or negative pregnancy test

Exclusion criteria

• Sequential Organ Failure Assessment (SOFA) < 4 on Day 0
• Patients <6 months post organ transplantation
• readmission to ICU during the current total hospital stay on Day 0
• patients admitted to ICU within 2 days after surgery
• patients admitted to ICU due to trauma
• elective surgery until Day 28 after first vaccination

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

803 participants in 2 patient groups, including a placebo group

IC43 100 mcg

Active Comparator group

Description:

IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein

Treatment:

Biological: IC43

Placebo

Placebo Comparator group

Description:

phosphate buffered saline solution containing 0,9 % NaCL

Treatment:

Drug: Placebo